Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study.

Gafanzer Belge Cansu Dumlupinar Tim Nestler Markus Klemke Peter Törzsök Emanuela Trenti Renate Pichler Wolfgang Loidl Yue Che Andreas Hiester Cord Matthies Martin Pichler Pia Paffenholz Luis A Kluth Mike Wenzel Jörg Sommer Julia Heinzelbecker Philipp Schriefer Alexander Winter Friedemann Zengerling Mario Wolfgang Kramer Marie Lengert Jana Frey Axel Heidenreich Christian WülfingArlo RadtkeKlaus Peter Dieckmann

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for testicular GCT patients.

Keyphrases